secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105010
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q2 net loss $33.9M; cash $996M; Merck milestone $10M triggered
--------------------------------------------------------------------

- Cash and short-term investments $996.0M at June 30, 2025, vs $1.03B at Dec 31, 2024.
- R&D expenses $34.7M (Q2 2025) vs $14.9M (Q2 2024); net loss $33.9M vs $6.0M.
- First patient dosed in lead Merck collaboration program triggered $10M milestone payment.
- Enrollment ongoing for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected H2 2025.
- R&D Day highlighted preclinical PSMA-TRACIr, TROP2-TRACTr, and CD19-ARM programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017025105010/0000950170-25-105010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017025105010/janx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer